We are translating years of basic research in the field of tumor immunology into novel immotherapeutic approaches to treat cancer. We specialize in the development of first-in-class monoclonal antibodies targeting novel immune checkpoints and regulators of the antitumoral immunity.
Our team focuses on the discovery and validation of novel targets that regulate the response to cancer immunotherapies. Our goal is to improve current anticancer strategies, response rates and patient survival. We rely on early partnerships with biotech and pharma companies to build our programs.
Our mission is to transform scientific insights in the field of tumor immunology
into improved response to cancer immunotherapies
Chief Executive Officer
Jeremy Bastid, PharmD, PhD, is a Pharmacist and Doctor in Oncology, specialized in immuno-oncology. He performed fundamental research in oncology at the INSERM U590 in the Centre Léon-Bérard, Lyon. Jeremy held several positions at the Hospices Civils de Lyon and at the University Claude Bernard Lyon 1. He is member and R&D Director of initiative OCTALFA, an organization dedicated to the inception of drug development companies. Jeremy is also Chief Development Officer of ORPHELIA Pharma, in charge of clinical development and BD.
Gilles Alberici, PharmD, PhD, is a Pharmacist and Doctor in Immunology. He founded and managed several biopharmaceutical and biotechnology companies in various therapeutic areas, notably immunosuppression and transplantation, acute leukemias and rare diseases. Since 2006, Gilles manages OCTALFA, a family-owned holding company specializing in Life Sciences, and the Dominique & Tom Alberici-Octalfa Corporate Foundation. He was elected Executive Chairman of ORPHELIA Pharma in 2015.
Chief Scientific Officer
Nathalie Bonnefoy, PhD, Doctor in Immunology, is Research Director at the INSERM. After her post-doctoral fellowship at La Jolla Institute for Allergy and Immunology in San Diego, she joined the INSERM U851 in Lyon (2003-2012) as a group leader. Since 2012, she is the head of the Immunity and Cancer team at the Institut de Recherche en Cancérologie de Montpellier – INSERM 1194, and its deputy director since 2019. Nathalie Bonnefoy is author of more than 80 scientific peer reviewed publications.
Founder and Scientific Advisor
Armand Bensussan, PhD, is director of the Skin Research Center and of the INSERM unit 976 at Saint-Louis Hospital in Paris, France. He was the past president of the French society of immunology. His scientific contributions have been in the field of basic immunology and onco-dermatology. He is author of 340 international scientific publications and editor of two scientific books. He is editorial board member of different international scientific journals and a member of the Human Cell Differentiation Molecules council.
Jean-François Eliaou, MD, PhD, is Professor of Medicine in Immunology. Head of the Department of Immunology at the University Hospital of Montpellier and Medical School of the Montpellier University, and member of INSERM U896, Jean-François Eliaou possesses recognized expertise in the field of Immunogenetics, Transplantation Immunology and autoimmune and chronic inflammatory diseases. He is President of the Société Francophone d’Histocompatibilité et d’Immunologie (SFHI) and author of more than 60 scientific peer reviewed publications.
Research lab, IRCM
Animal facility, Sanofi Biopark
Board of Directors
Chairman of the Board
Member of the Board
Isabelle Bou Antoun
Member of the Board